tirzepatide surmount-1 weight loss percent 72 weeks reduction with different doses of in Surmount 1 Analysis of Tirzepatide Acquisition Costs

Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes

If you prefer an oral medication, Rybelsus is a better fit for you

Tirzepatide's gastrointestinal effects, combined with plasma volume removal, can compromise hydration status

These medications have a low risk of causing low blood sugar when used alone but may increase this risk when combined with insulin or sulfonylureas

Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinsons disease